diuretic therapy in acute heart failure

---

quick recognition

Acute decompensated heart failure (ADHF) with congestion: dyspnoea, orthopnoea, peripheral oedema, elevated JVP, S3 gallop, pulmonary crackles. Diuretic resistance is present when adequate loop doses fail to achieve target urine output or weight loss.

Red flags for diuretic resistance: rising creatinine without effective diuresis, hypochloraemia (Cl⁻ < 96 mmol/L), hyponatraemia, persistent oedema despite furosemide ≥ 400 mg IV/day.

---

when to suspect diuretic resistance

• Chronic loop diuretic use (distal tubular hypertrophy)
• Gut oedema impairing oral absorption
• Hypochloraemic metabolic alkalosis (chloride depletion syndrome)
• Concurrent NSAID or nephrotoxin use
• Significant CKD (reduced tubular secretion of loop diuretics)
• Low cardiac output state (reduced renal perfusion)

---

the mullens protocol (2019)

Natriuresis-guided titration prevents clinical inertia. Based on Mullens W, et al. Eur J Heart Fail. 2019.

Step	Timepoint	Trigger / Check	Target	Action
1. Initial therapy	T+0	Fluid overload confirmed	—	IV loop diuretic: dose by GFR (see below), given as two divided boluses daily (q12h)
2. Quality check	T+2 h	Spot urine Na⁺	> 50–70 mmol/L	If below → double the dose; if above but low volume → increase frequency (e.g. q6h)
3. Quantity check	T+6 h	Cumulative urine output	> 150 mL/h (≈ 1000 mL at 6h)	If below → repeat bolus or start infusion
4. Efficiency check	T+24 h	kg weight loss ÷ total dose (in 40 mg units)	> 0.4 kg per 40 mg equivalent	If below → add sequential nephron blockade (acetazolamide upfront preferred; thiazide to break established resistance)
5. Rescue	Any	Hypochloraemia (Cl⁻ < 96 mmol/L) or hyponatraemia	—	Aggressive KCl repletion first; hypertonic saline protocol (SALT-HF) if refractory

what NOT to do at the outset

• Do not start at the home oral dose — IV bioavailability and gut oedema mandate dose escalation.
• Do not use continuous infusion preferentially over bolus for initial therapy — DOSE-AHF (2011) showed no difference in primary outcome, and infusions increase neurohormonal activation more than boluses (see below).
• Do not withhold GDMT (ACEi/ARNi, beta-blocker, MRA, SGLT2i) solely because of diuresis — wean loop first only if euvolaemic and hypotensive/azotaemic.
• Do not ignore developing hypernatraemia or metabolic alkalosis until they are severe — both predictably worsen with continued loop monotherapy and should be managed proactively (add thiazide for hypernatraemia; add acetazolamide and KCl for alkalosis).
• Do not interpret rising Na⁺ or metabolic alkalosis as evidence that the patient has been adequately diuresed — these are complications of how diuresis is being done (loop monotherapy), not indicators of euvolaemia.

---

core concepts

natriuresis vs. diuresis — the critical distinction

The therapeutic target is negative sodium balance, not negative fluid balance. Water follows electrolytes — oedema only resolves if sodium is removed. Excreting hypotonic urine without adequate natriuresis causes hypernatraemia and dehydration without decongestion.

• EVEREST (2007): Tolvaptan produced diuresis and weight loss but no mortality benefit — patients lost water, not sodium.
• ROSE-AHF (2013): Patients with net negative fluid balance but net positive sodium balance had worse outcomes. The prognostic signal tracks sodium, not water.

the mortality paradox: loops vs. GDMT

Loop diuretics inhibit NKCC2 in the thick ascending limb. The macula densa interprets reduced luminal Cl⁻ as hypovolaemia → renin release → RAAS upregulation. Loops decongest but activate the neurohormonal cascade that drives long-term mortality. GDMT blocks this surge.

Drug class	Target	Decongestion	Mortality benefit
Loop diuretics	Preload (haemodynamic)	+++	Neutral — TRANSFORM-HF (2023)
ACEi / ARNi	RAAS (neurohormonal)	+	Yes — remodelling
Beta-blockers	SNS (neurohormonal)	− (worsens acute)	Yes — arrhythmia/remodelling
MRA (spironolactone)	Aldosterone (neurohormonal)	+/− (weak diuretic)	Yes — antifibrotic — RALES (1999)
SGLT2 inhibitors	Metabolic/osmotic	++	Yes — pleiotropic — EMPEROR-Reduced (2021)
Vaptans	Free water excretion (V2 antagonist)	− (water only, no Na⁺)	No — EVEREST (2007)
Low-sodium diet	Volume load	+/−	Neutral — QoL only — SODIUM-HF (2022)

mechanisms of diuretic resistance

1. Braking phenomenon: Acute rebound sodium retention once drug effect wanes between boluses. Mitigated by more frequent dosing.
2. Distal tubular hypertrophy: Chronic loop blockade → DCT cell hypertrophy → avid downstream Na⁺ reabsorption. Broken by thiazides (distal blockade).
3. Chloride depletion syndrome (key driver): Loops waste Cl⁻. Low distal Cl⁻ delivery → macula densa chloride sensor → renin release (tubuloglomerular feedback). The kidney is a chloride sensor, not a sodium sensor — it avidly retains sodium because chloride is depleted. Prevented by acetazolamide (chloride-sparing) and aggressive KCl repletion.

---

management

step 1: loop diuretic foundation

Mechanism: Inhibits NKCC2 in the thick ascending limb (25% of filtered Na⁺ reabsorption).

dose is set by GFR; frequency is set by severity of fluid overload

Dose is determined by renal function — loop diuretics have a natriuretic threshold that rises as GFR falls. Underdosing in CKD is a common error.

GFR (eGFR mL/min/1.73m²)	Furosemide IV starting dose	Bumetanide IV equivalent
> 45	80 mg	2 mg
30–45	120 mg	3 mg
< 30	160–200 mg	4–5 mg

Frequency is determined by severity of fluid overload. Loop diuretics last ~6 hours; after the effect wanes, neurohormonal rebound causes avid sodium retention. Dose 1–4 times daily — not just once daily.

Mode — bolus preferred over continuous infusion:

• DOSE-AHF (2011): no difference in primary outcome between bolus and infusion.
• Bolus clears the natriuretic threshold reliably; the trough between doses allows neurohormonal suppression. Continuous infusions increase plasma renin activity more than boluses (CARRESS/DOSE sub-analysis).
• Practical: response can be assessed 2 hours after each bolus, enabling same-day titration.

Agent	Oral bioavailability	Clinical role
Furosemide	10–100% (erratic; worsened by gut oedema)	Standard first-line
Bumetanide	80–100% (stable)	Use if furosemide fails due to gut oedema; convenient dosing (1 amp = 2 mg = 80 mg furosemide)
Torsemide	80–100%	Longer half-life; reduces post-diuretic rebound
Metolazone	~65%	DCT booster; add-on to overcome distal hypertrophy

---

step 2: infusion if boluses fail

If boluses fail to achieve target urine Na⁺ despite dose escalation, switch to continuous infusion (e.g. furosemide 10–40 mg/hr). Maintains constant tubular drug concentration above the natriuretic threshold, preventing post-diuretic salt retention between boluses. Accept the neurohormonal trade-off and plan to add acetazolamide to compensate.

---

step 3: sequential nephron blockade

Synergism by blocking Na⁺ reabsorption at multiple nephron segments simultaneously.

proximal blockade — acetazolamide

• Site: Proximal convoluted tubule (carbonic anhydrase inhibitor).
• Dose: 500 mg IV once daily (oral bioavailability is reasonable — use 500 mg PO if IV unavailable; can go to 500 mg BID or 1000 mg BID in severe gut oedema).
• Evidence — ADVOR (2022): Acetazolamide + loop vs. placebo + loop. Successful decongestion 42% vs. 31% (NNT ≈ 9). No difference in 3-month mortality.
• Predictor of response: Benefit is magnified when baseline HCO₃⁻ ≥ 27 mmol/L (pre-existing metabolic alkalosis).
• Why it works — chloride preservation: Acetazolamide increases proximal NaHCO₃ excretion while sparing Cl⁻. By delivering more Cl⁻ to the macula densa, it suppresses renin release and prevents the neurohormonal brake on natriuresis. ADVOR data show chloride rises (or is maintained) with acetazolamide, even when it falls in the loop monotherapy arm.
• Key framing: ADVOR gave acetazolamide upfront to all patients, not only those with established resistance. It is a prevention strategy, not a rescue agent.
• Caveat: ADVOR excluded patients on SGLT2 inhibitors — since SGLT2i is now standard of care, synergy is extrapolated, not proven.
• Relative contraindications: Non-intubated patients with respiratory compromise (reduces metabolic compensation for respiratory acidosis); hypernatraemia (acetazolamide increases free water excretion and can worsen it — allow liberal drinking to compensate). Advanced liver disease (may increase encephalopathy risk). Avoid if GFR < 10 mL/min.

distal blockade — thiazides (metolazone)

• Site: Distal convoluted tubule (NCC inhibitor).
• Role: Overcomes distal tubular hypertrophy that develops after days of loop monotherapy. Used to break established resistance, not prevent it.
• Evidence: Weaker than acetazolamide — relies on small observational studies and the CLOROTIC (2023) trial (hydrochlorothiazide; improved weight loss but increased electrolyte disturbance, no mortality benefit).
• Metolazone pearls:
  • Give 30+ minutes before the loop diuretic.
  • Long half-life (14–24 h) — daily dosing is sufficient; avoid BID.
  • Replete K⁺ and Mg²⁺ before giving metolazone — expect massive K⁺ and Na⁺ wasting.
  • IV chlorothiazide is equally effective but costly; reserve for NPO patients.
  • Metolazone may also inhibit proximal tubule carbonic anhydrase, contributing to its efficacy in low-GFR states where other thiazides fail.
• Indapamide (5 mg PO daily) — thiazide-like alternative with longer half-life, glucose-neutral, some ICU deresuscitation evidence; less ADHF data than metolazone.

the metabolic alkalosis trap

Loop and thiazide diuretics both waste Cl⁻ and generate metabolic alkalosis. Alkalosis suppresses respiratory drive and — critically — further impairs natriuresis by reducing distal Cl⁻ delivery to the macula densa. This creates a self-reinforcing cycle of diuretic resistance.

Electrolyte pattern	Interpretation	Action
↓ Cl⁻, ↑ HCO₃⁻, normal Na⁺	Classic chloride depletion	KCl repletion first; add acetazolamide
↓ Cl⁻, ↑ HCO₃⁻, ↓ Na⁺	Dilutional + chloride depletion	KCl repletion; hypertonic saline protocol (SALT-HF) if refractory
↓ Na⁺, normal HCO₃⁻	True dilutional hyponatraemia	Fluid restriction; SGLT2i; consider tolvaptan
↑ Na⁺, normal or ↑ HCO₃⁻	Loop-induced free water loss (hypotonic urine)	Add thiazide to promote natriuresis; allow free water intake; do not interpret as adequate diuresis

---

step 4: rescue strategies

potassium chloride — the first-line chloride rescue

KCl repletion (not gluconate) is first-line for hypochloraemia — replenishes Cl⁻ directly while treating hypokalaemia. Target K⁺ > 4.0 mmol/L. Reduces the need for hypertonic saline in most cases.

hypertonic saline — SALT-HF (2024)

• Rationale: Provides Cl⁻ to restore macula densa sensing → suppresses renin → breaks the diuretic resistance loop.
• Indication: Hypochloraemia (Cl⁻ < 96 mmol/L) or refractory hyponatraemia despite adequate loop dosing and KCl repletion.
• Evidence: SALT-HF — neutral for 3h urine output overall, but improved 7-day weight loss; benefit concentrated in hypochloraemic subgroup.
• Role in the acetazolamide era: Largely superseded by upfront acetazolamide + KCl repletion. Most useful when neurohormonal activation is already entrenched or acetazolamide unavailable.

Protocol step	Detail
Load	150 mL of 3% NaCl IV over 30 min
Diuretic	High-dose loop (e.g. furosemide 250 mg IV) concurrently
Frequency	BID
Response check	Urine output 3–4 h post-dose; > 500 mL → continue
Stop if	Minimal output (risk of flash pulmonary oedema), Na⁺ > 150 mmol/L, or decongested

SGLT2 inhibitors — EMPULSE (2022)

• Mechanism: Inhibits SGLT2 in proximal tubule → osmotic glucosuria + natriuresis independent of the loop pathway. Also reduces proximal Na⁺ reabsorption via NHE3. Does not worsen neurohormonal activation.
• Evidence: Empagliflozin started during hospitalisation improved composite outcome at 90 days (EMPULSE).
• Practical use: Start during admission once SBP > 100 mmHg and eGFR ≥ 20 mL/min/1.73m². Continue indefinitely as GDMT.
• Monitoring: Genital mycotic infections, DKA (rare without T2DM), volume depletion if combined with aggressive loop dosing.

MRA — spironolactone / ATHENA-HF (2017)

• Mechanism: Aldosterone antagonist at the collecting duct → blocks ENaC-mediated Na⁺ reabsorption. Antifibrotic independently of diuresis. Genomic mechanism → slow onset; pharmacokinetics are too slow for acute rescue.
• Evidence: ATHENA-HF — high-dose spironolactone 100 mg/day vs. usual care in ADHF — no improvement in NT-proBNP, urine Na⁺, or clinical outcomes at 96 hours.
• Conclusion: MRA is GDMT for long-term mortality benefit (RALES), not an acute decongestion agent. Do not dose-escalate spironolactone expecting a meaningful acute diuretic response.
• Exception — cirrhosis/ascites: Secondary hyperaldosteronism is the primary driver of fluid retention; high-dose spironolactone (up to 400 mg/day) is effective and is the backbone of diuretic therapy here, unlike in primary cardiac failure.
• Monitoring: Hyperkalaemia (especially with CKD, ACEi/ARNi). Check K⁺ and creatinine at 1–2 weeks after initiation or dose change.
• Amiloride (5–20 mg PO daily) — faster-acting ENaC blocker than spironolactone (onset ~2h). Beyond its diuretic effect, amiloride counteracts loop-induced metabolic alkalosis, hypokalaemia, hypernatraemia, and hypomagnesaemia simultaneously — making it a useful proactive electrolyte-balancing partner in multi-agent regimens. Risk of hyperkalaemia (avoid if K⁺ >5.0 or GFR <10). Use amiloride, never triamterene — triamterene causes nephrolithiasis, interstitial nephritis, and AKI.

ultrafiltration — CARRESS-HF (2012)

• Mechanism: Extracorporeal removal of isotonic fluid; bypasses tubular resistance entirely.
• Evidence: CARRESS-HF — ultrafiltration vs. stepped pharmacological therapy. Ultrafiltration was inferior: worse creatinine at 96 hours, no difference in weight loss, more adverse events.
• Why it failed: Fixed filtration rates often exceed the patient’s plasma refill rate → intravascular depletion → AKI, even as peripheral oedema persists.
• Current role: Last resort for uraemia/acidosis or refractory congestion despite maximal sequential nephron blockade. Not a first- or second-line strategy for diuretic resistance.

peritoneal dialysis

• Consider in diuretic-resistant patients with RV failure, haemodynamic instability precluding extracorporeal UF, or advanced CKD. Fewer haemodynamic shifts than UF, no anticoagulation required, directly targets intra-abdominal hypertension. Recognised in the AHA 2022 scientific statement on home dialysis therapies. Observational data show reduced HF hospitalisations and symptom improvement.

---

step 5: transition and discharge planning

the stability rule

Observe on oral diuretics for 24–48 hours before discharge. Ensure weight remains stable without rebound fluid accumulation. The post-discharge period is the highest-risk window for readmission — inadequate decongestion at discharge is the primary driver.

IV → oral dose conversion

Furosemide has ~50% oral bioavailability (erratic, worsened by gut oedema). Double the IV dose for the oral equivalent.

If gut oedema was a persistent issue during admission, consider switching to torsemide at discharge (80–100% bioavailability). TRANSFORM-HF (2023) showed no mortality difference vs. furosemide, but consistent absorption makes torsemide preferable when furosemide response has been unreliable.

GDMT optimisation — STRONG-HF (2022)

Early aggressive GDMT up-titration before or at discharge reduces 180-day readmission and death. Decongest aggressively first → lowest effective maintenance loop dose → maximise GDMT simultaneously.

Timepoint	Action
Day 1–2 of admission	Confirm or initiate SGLT2i (EMPULSE strategy)
Pre-discharge	ACEi/ARNi, beta-blocker, MRA at target or maximally tolerated doses
Pre-discharge	Transition IV → oral loop; double the IV dose for PO equivalent
Day 1–2 post-discharge	Check electrolytes, creatinine, blood pressure
1–2 weeks	Outpatient visit: adjust GDMT, reassess volume status

sodium restriction — SODIUM-HF (2022)

Low-sodium diet (< 1500 mg/day) showed no mortality or hospitalisation benefit vs. usual care; QoL improved slightly. Moderate restriction (< 2000 mg/day) is reasonable for symptoms; aggressive restriction is not evidence-based.

---

safety and monitoring

Complication	Mechanism	Prevention / Management
Hypokalaemia	Loop + thiazide K⁺ wasting	Aggressive KCl replacement; target K⁺ > 4.0 mmol/L; replete before metolazone
Hypomagnesaemia	Loop diuretic Mg²⁺ wasting	Replete Mg²⁺ before K⁺ (required for effective K⁺ repletion); target Mg²⁺ > 0.8 mmol/L
Hypochloraemia	Cl⁻ wasting → metabolic alkalosis → renin activation	KCl repletion (chloride-replete form only); acetazolamide; hypertonic saline if refractory
Hyponatraemia	Thiazide diluting segment block or free water retention	Distinguish mechanism — loops often correct; thiazides worsen; stop thiazide if Na⁺ < 125
AKI	Haemodynamic single-nephron GFR change; rarely tubular injury	Permissive approach if actively decongesting; true stop trigger: rising Cr without diuresis or hypotension
Ototoxicity	Rapid high-dose IV loop (especially ethacrynic acid)	Max single bolus: 250–300 mg furosemide; max daily: 600–1500 mg. Infuse at ≤4 mg/min furosemide. Bumetanide max 12 mg/day (ACC 2024). Bumetanide preferred at very-high doses (lower ototoxic potential)

---

special populations

HF with preserved ejection fraction (HFpEF)

• Higher sensitivity to over-diuresis — narrow therapeutic window between congestion and pre-renal AKI.
• SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce HF hospitalisation in HFpEF and are preferred GDMT.
• Aggressive sequential nephron blockade carries higher AKI risk; titrate cautiously.

cardiorenal syndrome

• Loop diuretics may worsen renal perfusion in low-output states — consider inotrope support (dobutamine) to improve forward flow before escalating diuresis.
• Torsemide or bumetanide preferred over furosemide in significant CKD (more predictable tubular secretion and pharmacokinetics).
• Ultrafiltration may be appropriate earlier in CKD stage 4–5 if pharmacological options are exhausted.

right heart failure / RV-dominant congestion

• Elevated right-sided pressures → hepatic congestion → gut oedema → impaired oral absorption. Use IV loop diuretics until decongested.
• Hepatic congestion reduces hepatic drug metabolism — watch for drug accumulation.
• Avoid over-diuresis: RV is preload-dependent; aggressive volume removal can drop RV output and worsen LV filling.

cirrhosis / ascites

• Secondary hyperaldosteronism is the primary driver of fluid retention — spironolactone (up to 400 mg/day) is the backbone of diuretic therapy here, unlike in primary cardiac failure where its acute diuretic effect is negligible (ATHENA-HF).
• Loops added as needed; hyponatraemia and AKI are frequent complications requiring careful titration.

---

key trials summary

Trial	Year	N	Intervention	Key result
EVEREST	2007	4,133	Tolvaptan vs. placebo in ADHF	Short-term weight loss and dyspnoea improved; no mortality benefit or reduction in HF hospitalisation — water without sodium does not decongest
DOSE-AHF	2011	308	High vs. low dose; bolus vs. infusion	High dose superior for symptom relief and fluid loss; bolus = infusion on primary outcome
CARRESS-HF	2012	188	Ultrafiltration vs. stepped pharmacotherapy	Pharmacotherapy superior; UF associated with more AKI
ROSE-AHF	2013	360	Dopamine/nesiritide vs. placebo in ADHF	Neutral; established that positive sodium balance (not fluid balance) predicts worse outcomes
ATHENA-HF	2017	360	High-dose spironolactone 100 mg vs. usual care in ADHF	No acute decongestion benefit
ADVOR	2022	519	Acetazolamide 500 mg IV + loop vs. loop alone (upfront)	Improved decongestion (42% vs. 31%, NNT ≈ 9); no mortality benefit; chloride preserved
EMPULSE	2022	530	Empagliflozin started in-hospital vs. placebo	Improved composite outcome at 90 days
STRONG-HF	2022	1,078	Early aggressive GDMT up-titration vs. usual care	Reduced 180-day readmission and death
CLOROTIC	2023	230	Hydrochlorothiazide + loop vs. loop alone	Improved weight loss; more electrolyte disturbance; no mortality benefit
PUSH-AHF	2023	310	Natriuresis-guided diuretic titration vs. usual care	Greater natriuresis and diuresis; no improvement in weight loss, LOS, or clinical outcomes — validates urine Na⁺-guided approach but reinforces that decongestion alone does not improve prognosis
TRANSFORM-HF	2023	2,859	Torsemide vs. furosemide at discharge	No difference in all-cause mortality or HF hospitalisation at 12 months
SALT-HF	2024	182	Hypertonic saline + loop vs. loop alone	Neutral for 3h urine output overall; improved 7-day weight loss; benefit concentrated in hypochloraemic patients
Reddy et al. (pilot)	2026	19	Very-high dose loop (1000 mg furosemide eq.) vs. conventional 2× home dose	Greater 24h urine output (5283 vs. 2813 mL, p=0.025); greater venous pressure reduction; no excess AKI or hypotension